Roman Yatsyshyn

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7785227/publications.pdf

Version: 2024-02-01

11	524	7	10
papers	citations	h-index	g-index
11	11	11	736 citing authors
all docs	docs citations	times ranked	

#	Article	lF	CITATIONS
1	A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Research and Therapy, 2016, 18, 82.	3.5	148
2	A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases, 2017, 76, 58-64.	0.9	146
3	Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study. Annals of the Rheumatic Diseases, 2018, 77, 234-240.	0.9	107
4	Comparing biosimilar SB2 with reference infliximab after 54 weeks of a double-blind trial: clinical, structural and safety results. Rheumatology, 2017, 56, 1771-1779.	1.9	49
5	Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial. Rheumatology, 2021, 60, 2277-2287.	1.9	36
6	Pulmonary involvement in systemic sclerosis: exploring cellular, genetic and epigenetic mechanisms. Rheumatology International, 2020, 40, 1555-1569.	3.0	11
7	Prostate involvement in granulomatosis with polyangiitis. Rheumatology International, 2019, 39, 1269-1277.	3.0	8
8	COVID-19 from a rheumatology perspective: bibliometric and altmetric analysis. Rheumatology International, 2021, 41, 2091-2103.	3.0	8
9	Rheumatology in Ukraine. Rheumatology International, 2020, 40, 175-182.	3.0	6
10	Challenges in diagnosis of limited granulomatosis with polyangiitis. Rheumatology International, 2021, 41, 1337-1345.	3.0	5
11	SAT0170â€A NOVEL FORMULATION OF CT-P13 FOR SUBCUTANEOUS ADMINISTRATION: 30 WEEK RESULTS FI A PART 2 OF PHASE I/III RANDOMIZED CONTROLLED TRIAL IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, ,		O